What question did this study set out to answer?

This research aims to evaluate the long-term efficacy and safety of nemolizumab in patients with moderate-to-severe atopic dermatitis over 48 weeks.

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates maintained skin responses in atopic dermatitis patients, highlighting efficacy and safety.

This research aims to evaluate the long-term efficacy and safety of nemolizumab in patients with moderate-to-severe atopic dermatitis over 48 weeks.
Two global phase 3 trials, ARCADIA 1 and 2, with 507 clinical responders rerandomized to different nemolizumab dosing regimens.
Patients received nemolizumab 30 mg every 4 weeks, every 8 weeks, or placebo, combined with topical therapy.
Efficacy measured by Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) at weeks 16 and 48.
At week 48, 61.5% of patients receiving nemolizumab Q4W achieved IGA success compared to 49.7% in the withdrawal group (Δ, 11.8%, 95% CI 1.3-22.3).
74.3% of patients in the nemolizumab Q8W group maintained EASI-75 response versus 63.9% in the withdrawal group (Δ, 11.8%, 95% CI 2.1-21.5).
Adverse events were reported similarly across treatment groups, ranging from 53.5% to 58.3%.

Wollenberg et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates maintained skin responses in atopic dermatitis patients, highlighting efficacy and safety.

This research aims to evaluate the long-term efficacy and safety of nemolizumab in patients with moderate-to-severe atopic dermatitis over 48 weeks.
Two global phase 3 trials, ARCADIA 1 and 2, with 507 clinical responders rerandomized to different nemolizumab dosing regimens.
Patients received nemolizumab 30 mg every 4 weeks, every 8 weeks, or placebo, combined with topical therapy.
Efficacy measured by Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) at weeks 16 and 48.
At week 48, 61.5% of patients receiving nemolizumab Q4W achieved IGA success compared to 49.7% in the withdrawal group (Δ, 11.8%, 95% CI 1.3-22.3).
74.3% of patients in the nemolizumab Q8W group maintained EASI-75 response versus 63.9% in the withdrawal group (Δ, 11.8%, 95% CI 2.1-21.5).
Adverse events were reported similarly across treatment groups, ranging from 53.5% to 58.3%.

Wollenberg et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark